
|Videos|November 9, 2022
LUGPA 2022: Dr. Shore on the significance of genetic testing in prostate cancer
Author(s)Urology Times staff
“There’s a lot of clinical utility to genetic testing, and there are familial implications and clinical trial implications,” explains Neal Shore, MD.
Advertisement
Neal Shore, MD, explains how genetic testing has become an essential component of the treatment paradigm for patients with prostate cancer. Shore is co-chairing the CME program at the
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
3
FDA grants tentative approval to generic olaparib tablets across previously approved indications
4
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
5












